CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Radiation therapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug213 ArtemiC Wiki 0.71
drug2864 laboratory biomarkers Wiki 0.71
drug2903 muscle ultrasound Wiki 0.71
drug1086 Hydroxychloroquine Wiki 0.07
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D009220 Myositis NIH 0.71
D009205 Myocarditis NIH 0.27
D007239 Infection NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D003141 Communicable Diseases NIH 0.06
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0100614 Myositis HPO 0.71
HP:0012819 Myocarditis HPO 0.27

There are 2 clinical trials

Clinical Trials

1 A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)

The researchers are doing this study to find out whether the study drug hydroxychloroquine can prevent infection with the COVID-19 virus, compared with placebo, in people who are receiving radiation therapy for their cancer. The placebo used in this study is a tablet that looks the same as the study drug and is taken in the same way, but it does not contain any active ingredients.

NCT04381988 COVID-19 Cancer Drug: Hydroxychloroquine Other: Placebo Radiation: Radiation therapy

Primary Outcomes

Description: Any patients who are enrolled and subsequently test positive for SARS-CoV-2 by RT-PCR (outside RT-PCR test results allowed) at any point during the 9 weeks following enrollment will be an event that is considered in the 9-week SARS-CoV-2 infection rate primary endpoint.

Measure: cumulative incidence of SARS-CoV-2 infection

Time: within 9 weeks from randomization

Secondary Outcomes

Description: Patients who are positive for SARS-CoV-2 (as defined above) who develop a new oxygen requirement attributable to COVID-19, tachypnea (RR > 20), or those who require hospitalization due to COVID-19 will be considered to have severe COVID-19.

Measure: cumulative incidence of severe COVID-19 or death

Time: within 12 weeks of randomization

2 Vented COVID: A Phase II Study Of The Use Of Ultra Low-Dose Bilateral Whole Lung Radiation Therapy in the Treatment Of Critically Ill Patients With COVID-19 Respiratory Compromise

Low doses of radiation in the form of chest X-rays have been used to treat people with pneumonia. This treatment was found to be effective by reducing inflammation and with minimal side effects. However, it was an expensive treatment and was eventually replaced with less costly treatments such as antibiotics. Radiation has also been shown in some animal experiments to reduce some types of inflammation. Some patients diagnosed with COVID-19 pneumonia will experience worsening disease, which can become very serious, requiring the use of a ventilator. This is caused by inflammation in the lung from the virus and the immune system. For this study, the x-ray given is called radiation therapy. Radiation therapy uses high-energy X-ray beams from a large machine to target the lungs and reduce inflammation. Usually, it is given at much higher doses to treat cancers. The purpose of this study is to find out if adding a single treatment of low-dose x-rays to the lungs might reduce the amount of inflammation in the lungs from a COVID-19 infection, which could help a patient to breathe without use of a ventilator.

NCT04427566 COVID-19 Radiation: Radiation therapy

Primary Outcomes

Description: Death date of subjects will be collected from the date of radiation up to 1 month post radiation dose

Measure: Mortality rate of subjects treated with whole lung low-dose radiation

Time: up to 28 days post radiation delivery

Secondary Outcomes

Description: Subject survival will be collected in number of days through 18 months post treatment

Measure: Survival rate of subjects treated with whole lung low-dose radiation

Time: up to 18 months post radiation delivery

Description: Number of intensive care days

Measure: Change in number of Intensive care unit days

Time: up to 28 days post radiation delivery

Description: Number of days using supplemental oxygen

Measure: Change in number of days using supplemental oxygen

Time: up to 28 days post radiation delivery

Description: Oxygenation index/oxygen saturation until extubation

Measure: Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated

Time: up to 28 days post radiation

Description: Measure as a percent, the amount of pneumonia involvement of each lung segment (right upper lobe, right middle lobe, right lower lobe, left upper lobe and left lower lobe) from chest CT images at day 7, 14 and 28. Each lung segment can have involvement from 0 % (no involvement) up to 100% (complete pneumonia involvement of segment)

Measure: Quantitation of Lung Involvement using Chest CT

Time: up to 28 days post radiation

Description: Semi-quantitation of ground glass opacities or lung opacification with a score of 0-5 from Chest CT images at day 7, 14 and 28 for each of the 5 lobes of the lungs. The scoring system is as follows: 0, no involvement; 1, <5% involvement; 2, 25% involvement, 3, 26-49% involvement; 4, 50-75% involvement; and 5, >75% involvement.

Measure: Quantitation of Lung Opacities using Chest CT

Time: up to 28 days post radiation

Description: Determine viral titers at baseline, days 7, 14 and 28.

Measure: SARS-CoV2 viral titers

Time: up to 28 days

Description: Review adverse events, including severity and duration, for all subjects to determine safety of the radiation treatment for pneumonia due to COVID-19.

Measure: Incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs

Time: up to 28 days

Description: Performance status will be evaluated using the Karnofsky Performance Scale Index at baseline, 7, 14 and 28 days post radiation dose. Scores range from 100 (normal, no complaints) to 0 (dead). A higher number indicates the ability to carry out normal daily activities.

Measure: Change in performance status after low dose radiation to lungs

Time: up to 28 days

No related HPO nodes (Using clinical trials)